Shariat SF - Search Results

1

p53 expression in patients with advanced urothelial cancer of the urinary bladder.

Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, Lotan Y. Shariat SF, et al. BJU Int. 2010 Feb;105(4):489-95. doi: 10.1111/j.1464-410X.2009.08742.x. Epub 2009 Jul 31. BJU Int. 2010. PMID: 19659466

2

Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder.

Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, Lerner SP. Shariat SF, et al. Urology. 2000 Nov 1;56(5):735-40. doi: 10.1016/s0090-4295(00)00756-1. Urology. 2000. PMID: 11068290

3

E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder.

Shariat SF, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, Lerner SP. Shariat SF, et al. Urology. 2001 Jan;57(1):60-5. doi: 10.1016/s0090-4295(00)00892-x. Urology. 2001. PMID: 11164145

4

E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.

Byrne RR, Shariat SF, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. Byrne RR, et al. Among authors: shariat sf. J Urol. 2001 May;165(5):1473-9. J Urol. 2001. PMID: 11342899

5

Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens.

Tokunaga H, Shariat SF, Green AE, Brown RM, Zhou JH, Benedict WF, Lerner SP. Tokunaga H, et al. Among authors: shariat sf. Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):16-22. doi: 10.1016/s0360-3016(01)01586-3. Int J Radiat Oncol Biol Phys. 2001. PMID: 11516846

6

Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder.

Kim JH, Shariat SF, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, Lerner SP. Kim JH, et al. Among authors: shariat sf. Cancer. 2001 Sep 15;92(6):1475-83. doi: 10.1002/1097-0142(20010915)92:6<1475::aid-cncr1472>3.0.co;2-x. Cancer. 2001. PMID: 11745225

7

Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma.

Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Shariat SF, et al. Cancer. 2001 Dec 15;92(12):2985-92. doi: 10.1002/1097-0142(20011215)92:12<2985::aid-cncr10175>3.0.co;2-5. Cancer. 2001. PMID: 11753975

8

Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.

Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Andrews B, et al. Among authors: shariat sf. J Urol. 2002 Mar;167(3):1475-81. J Urol. 2002. PMID: 11832773

9

Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.

Casella R, Shariat SF, Monoski MA, Lerner SP. Casella R, et al. Among authors: shariat sf. Cancer. 2002 Dec 15;95(12):2494-9. doi: 10.1002/cncr.10989. Cancer. 2002. PMID: 12467062 Free article.

10

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.

Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Shariat SF, et al. J Urol. 2003 Mar;169(3):938-42. doi: 10.1097/01.ju.0000043638.89552.ed. J Urol. 2003. PMID: 12576817

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,908 results

Search Page

Filters